Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from IR-MPH to OROS-MPH in ADHD
NCT00758160Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD), sponsored by Johnson & Johnson. Started Mar 2008; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00758160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758160.